NDAVAGINALGEL
Approved
May 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
6/8 — Strong
PHEXXI (lactic acid, l-, citric acid monohydrate, and potassium bitartrate) by Evofem Biosciences is studies, phexxi produced a normal vaginal ph range (ph 3. Approved for pregnancy in females of reproductive potential for use. First approved in 2020.
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PHEXXI is a non-hormonal vaginal gel contraceptive containing lactic acid, citric acid monohydrate, and potassium bitartrate that prevents pregnancy by maintaining vaginal pH 3.5–4.5, which reduces sperm motility in the presence of semen. Approved in May 2020, it represents a novel mechanism in reproductive health for women seeking hormone-free birth control. The product is indicated for pregnancy prevention in females of reproductive potential.
$0.086MPart D
Peak6.4 years to LOEProduct is at peak stage with minimal current Part D penetration (~$86K), indicating either nascent adoption or market challenges that could affect team stability and investment.
Mechanism of Action
studies, Phexxi produced a normal vaginal pH range (pH 3.5 – 4.5) in the presence of semen. In clinical studies, post-coital testing demonstrated pH < 5 in the majority of subjects, and sperm motility reduction.
Indications (1)
Clinical Trials (1)
Study of Contraceptive Efficacy & Safety of Phexxi™ (Previously Known as Amphora) Gel Compared to Conceptrol Vaginal Gel
Started Apr 2011
3,389 enrolled
Contraception
Career Relevance
PHEXXI represents a niche, innovation-driven product with significant commercial challenges reflected in minimal Part D penetration ($86K annually on ~200 claims); career roles will concentrate in commercial teams driving market adoption against entrenched competitors. Working on PHEXXI offers exposure to reproductive health innovation and non-hormonal contraceptive positioning, but limited internal mobility given thin clinical pipeline and modest market traction.
Worked on PHEXXI at Evofem Biosciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.